Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors

被引：0
|
作者：
Heymach, John [1 ]
Yamamoto, Noboru [2 ]
Opdam, Frans [3 ]
Barve, Minal [4 ]
Tu, Hai-Yan [5 ]
Wu, Yi-Long [5 ]
Schroeter, Lukas [6 ]
Sadrolhefazi, Behbood [7 ]
Serra, Josep [8 ]
Yoh, Kiyotaka [9 ]
Berz, David [10 ]
机构：
[1] Univ Texas Houston, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA
[2] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[3] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[4] Mary Crowley Canc Res, Dallas, TX USA
[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] 8 Boehringer Ingelheim Espana SA, Barcelona, Spain
[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[10] Valkyrie Clin Trials, Los Angeles, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA01.01
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [41] Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
    Erika Hamilton
    Kimberly Blackwell
    Amy C Hobeika
    Timothy M Clay
    Gloria Broadwater
    Xiu-Rong Ren
    Wei Chen
    Henry Castro
    Frederic Lehmann
    Neil Spector
    Junping Wei
    Takuya Osada
    H Kim Lyerly
    Michael A Morse
    Journal of Translational Medicine, 11
  • [42] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Jian Zhang
    Junning Cao
    Jin Li
    Yifan Zhang
    Zhiyu Chen
    Wei Peng
    Si Sun
    Naiqing Zhao
    Jiachen Wang
    Dafang Zhong
    Xiaofang Zhang
    Jing Zhang
    Journal of Hematology & Oncology, 7
  • [43] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian
    Cao, Junning
    Li, Jin
    Zhang, Yifan
    Chen, Zhiyu
    Peng, Wei
    Sun, Si
    Zhao, Naiqing
    Wang, Jiachen
    Zhong, Dafang
    Zhang, Xiaofang
    Zhang, Jing
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [44] A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Zhang, Pin
    Wang, Lin
    Zhen, Yueying
    Wang, Zhihong
    Zhang, Hesheng
    Jones, Richard
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
  • [45] HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells
    Hirata, A
    Hosoi, F
    Miyagawa, N
    Ueda, S
    Naito, S
    Fujii, T
    Kuwano, N
    Ono, M
    CANCER RESEARCH, 2005, 65 (10) : 4253 - 4260
  • [46] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Kudla, A.
    Adiwijaya, B.
    Paragas, V.
    Richards, D.
    Braiteh, F.
    Garcia, A. A.
    Denlinger, C. S.
    Conkling, P.
    Edenfield, W. J.
    Anthony, S.
    Hellerstedt, B.
    Raju, R.
    Becerra, C.
    Harb, W.
    Smith, D.
    Kawash, K.
    Frye, S.
    McDonagh, C. F.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [47] A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
    Hong, M. H.
    Spira, A. I.
    Lee, K. H.
    Cho, E. K.
    Han, J-Y.
    Shim, B. Y.
    Lee, J-S.
    Kao, S. C-H.
    Kim, S-W.
    Khattak, A.
    Patel, M.
    Xu, R.
    Wang, J.
    Ariazi, E.
    Daemen, A.
    Maneval, E. Chow
    Multani, P. S.
    Patel, R.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [48] A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
    Zhou, Chenfei
    Wang, Bin
    Teng, Christina
    Yang, Hui
    Piha-Paul, Sarina A.
    Richardson, Gary
    Malalasekera, Ashanya
    Sun, Yajun
    Wang, Wei
    Liu, Jieqiong
    Shi, Yan
    Zhan, Xianbao
    Lemech, Charlotte
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [49] An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
    Arkenau, H. -T.
    Italiano, A.
    Mak, G.
    Toulmonde, M.
    Baird, R. D.
    Garcia-Corbacho, J.
    Plummer, R.
    Flynn, M.
    Forster, M.
    Wilson, R. H.
    Tosi, D.
    Adenis, A.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Arimura, A.
    Deva, S.
    Spicer, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 17 - 23
  • [50] Targeting HER2 Exon 20-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib
    Han, H.
    Li, S.
    Chen, T.
    Fitzgerald, M.
    Liu, S.
    Peng, C.
    Tang, K.
    Cao, S.
    Chouitar, J.
    Wu, J.
    Peng, D.
    Deng, J.
    Gao, Z.
    Baker, T.
    Li, F.
    Zhang, H.
    Pan, Y.
    Ding, H.
    Hu, H.
    Pyon, V.
    Thakurdin, C.
    Papadopoulos, E.
    Tang, S.
    Gonzalvez, F.
    Chen, H.
    Rivera, V.
    Brake, R.
    Vincent, S.
    Wong, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S918 - S918
12345